KR20230152177A - N-아세틸시스테인 아미드를 사용한 색소성 망막염의 치료 - Google Patents

N-아세틸시스테인 아미드를 사용한 색소성 망막염의 치료 Download PDF

Info

Publication number
KR20230152177A
KR20230152177A KR1020237036499A KR20237036499A KR20230152177A KR 20230152177 A KR20230152177 A KR 20230152177A KR 1020237036499 A KR1020237036499 A KR 1020237036499A KR 20237036499 A KR20237036499 A KR 20237036499A KR 20230152177 A KR20230152177 A KR 20230152177A
Authority
KR
South Korea
Prior art keywords
naca
administered
retinitis pigmentosa
acid
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237036499A
Other languages
English (en)
Korean (ko)
Inventor
피터 에이 캄포치아로
다니엘 하트만
Original Assignee
더 존스 홉킨스 유니버시티
나쿠이티 파마슈티컬스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 존스 홉킨스 유니버시티, 나쿠이티 파마슈티컬스, 인코포레이티드 filed Critical 더 존스 홉킨스 유니버시티
Publication of KR20230152177A publication Critical patent/KR20230152177A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
KR1020237036499A 2014-11-07 2015-11-06 N-아세틸시스테인 아미드를 사용한 색소성 망막염의 치료 Pending KR20230152177A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462076594P 2014-11-07 2014-11-07
US62/076,594 2014-11-07
KR1020227009489A KR20220039853A (ko) 2014-11-07 2015-11-06 N-아세틸시스테인 아미드를 사용한 색소성 망막염의 치료
PCT/US2015/059589 WO2016073931A1 (en) 2014-11-07 2015-11-06 Treatment of retinitis pigmentosa with n-acetylcysteine amide

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227009489A Division KR20220039853A (ko) 2014-11-07 2015-11-06 N-아세틸시스테인 아미드를 사용한 색소성 망막염의 치료

Publications (1)

Publication Number Publication Date
KR20230152177A true KR20230152177A (ko) 2023-11-02

Family

ID=55909913

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020237036499A Pending KR20230152177A (ko) 2014-11-07 2015-11-06 N-아세틸시스테인 아미드를 사용한 색소성 망막염의 치료
KR1020177015227A Ceased KR20170109527A (ko) 2014-11-07 2015-11-06 N-아세틸시스테인 아미드를 사용한 색소성 망막염의 치료
KR1020227009489A Ceased KR20220039853A (ko) 2014-11-07 2015-11-06 N-아세틸시스테인 아미드를 사용한 색소성 망막염의 치료

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020177015227A Ceased KR20170109527A (ko) 2014-11-07 2015-11-06 N-아세틸시스테인 아미드를 사용한 색소성 망막염의 치료
KR1020227009489A Ceased KR20220039853A (ko) 2014-11-07 2015-11-06 N-아세틸시스테인 아미드를 사용한 색소성 망막염의 치료

Country Status (11)

Country Link
US (2) US12472157B2 (enExample)
EP (2) EP3214934A4 (enExample)
JP (5) JP2017533969A (enExample)
KR (3) KR20230152177A (enExample)
CN (2) CN108498495A (enExample)
AU (4) AU2015342831B2 (enExample)
BR (1) BR112017009584A2 (enExample)
CA (1) CA2967327C (enExample)
HK (1) HK1252822A1 (enExample)
RU (1) RU2711913C2 (enExample)
WO (2) WO2016073829A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10752593B2 (en) 2018-12-28 2020-08-25 Endogena Therapeutics, Inc. Compounds for use as therapeutically active substances in the treatment of retinal diseases
AU2015342831B2 (en) 2014-11-07 2019-09-12 Nacuity Pharmaceuticals, Inc. Treatment of retinitis pigmentosa with N-acetylcysteine amide
JP6849867B2 (ja) 2014-11-11 2021-03-31 ザ・ジョンズ・ホプキンス・ユニバーシティー 眼疾患を有する対象の治療に有用なバイオマーカー
US11548851B2 (en) 2017-09-20 2023-01-10 Nacuity Pharmaceuticals, Inc. Method for preparation of n-acetyl cysteine amide and derivatives thereof
AU2018338103B2 (en) 2017-09-20 2020-07-16 Nacuity Pharmaceuticals, Inc. Method for preparation of N-acetyl cysteine amide and derivatives thereof
US11091433B2 (en) 2017-09-20 2021-08-17 Nacuity Pharmaceutials, Inc. Method for preparation of N-acetyl cysteine amide and derivatives thereof
US20190135741A1 (en) * 2017-11-09 2019-05-09 Nacuity Pharmaceuticals, Inc. Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress
US20190151271A1 (en) * 2017-11-21 2019-05-23 The Johns Hopkins University Compositions and methods for treatment of eye diseases
JP2021531340A (ja) * 2018-07-09 2021-11-18 フォンダシヨン、アジール、デ、アブグルスFondation Asile Des Aveugles 眼障害を治療するためのｐｒｃ２サブユニットの阻害
CN109096161B (zh) * 2018-08-24 2020-10-27 武汉远大弘元股份有限公司 一种n-乙酰半胱氨酸的制备方法
US10807973B2 (en) 2018-12-28 2020-10-20 Endogena Therapeutics, Inc. Compounds for use as therapeutically active substances in the treatment of retinal diseases
US12245998B2 (en) 2019-01-11 2025-03-11 Nacuity Pharmaceuticals, Inc. N-acetylcysteine amide (NACA) and (2R,2R′)-3,3′ disulfanediyl bis(2-acetamidopropanamide) (diNACA) for the prevention and treatment of radiation pneumonitis and treatment of pulmonary function in Cystic Fibrosis
KR102745520B1 (ko) 2019-01-11 2024-12-23 나쿠이티 파마슈티컬스, 인코포레이티드 방사선 피부염을 방지 및 치료하고 피부 라이트닝 또는 피부 화이트닝을 위한 n-아세틸시스테인 아미드(naca) 및 (2r,2r')-3,3'-디설판디일 비스(2-아세트아미도프로판아미드)(dinaca)
US11766413B2 (en) 2019-01-11 2023-09-26 Nacuity Pharmaceuticals, Inc. Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with n-acetylcysteine amide (NACA) or (2R,2R′)-3,3′-disulfanediyl BIS(2-acetamidopropanamide)(DiNACA)
CN115151251A (zh) * 2020-01-24 2022-10-04 纳崔泰制药有限公司 用于治疗氧化应激的疾病和损伤的前药

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3252866A (en) 1965-06-28 1966-05-24 Mead Johnson & Co 2-hydrocarbon substituted-amido mercaptopropionamides in hair waving compositions and processes
US5874468A (en) 1996-12-26 1999-02-23 Yissum Brain targeted low molecular weight hydrophobic antioxidant compounds
US6420429B1 (en) 1997-12-23 2002-07-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Brain targeted low molecular weight hydrophobic antioxidant compounds
WO2002100293A2 (en) 2001-06-13 2002-12-19 Webb-Waring Institute For Biomedical Research A diagnostic and prognostic method for evaluating ocular inflammation and oxidative stress and the treatment of the same
BE1014949A3 (fr) 2001-08-14 2004-07-06 Probiox Procede de detection de stress oxydant et trousse pour sa mise en oeuvre.
AU2003247144B2 (en) 2002-08-02 2007-11-29 Mor Research Applications Ltd. Treatment of multiple sclerosis with brain targeted anti oxidant compounds
EP1551399A4 (en) 2002-09-30 2011-01-05 Mark A Babizhayev METHOD FOR THE TOPICAL TREATMENT OF EYE DISEASES AND COMPOSITION AND DEVICE FOR THIS TREATMENT
JP2005350405A (ja) 2004-06-11 2005-12-22 Shiseido Co Ltd 重合抑制剤および即時型黒化防止用皮膚外用剤
US8993627B2 (en) 2005-04-21 2015-03-31 Sentient Lifesciences, Inc. N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
US20090234011A1 (en) 2005-04-21 2009-09-17 Goldstein Glenn A N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
CN101232877A (zh) * 2005-04-21 2008-07-30 格伦·A·戈尔茨坦 治疗与氧化应激有关的疾病和病症的n-乙酰半胱氨酸酰胺（nac酰胺）
JP4840804B2 (ja) 2006-01-20 2011-12-21 学校法人慶應義塾 酸化ストレスの判定方法
WO2010048716A1 (en) 2008-10-29 2010-05-06 Pacific Therapeutics Ltd. Composition and method for treating fibrosis
US20120150029A1 (en) 2008-12-19 2012-06-14 University Of Miami System and Method for Detection and Monitoring of Ocular Diseases and Disorders using Optical Coherence Tomography
US9173423B2 (en) 2009-07-31 2015-11-03 The Iams Company Animal food kibble with electrostatically adhered dusting
WO2011044230A2 (en) 2009-10-06 2011-04-14 Goldstein Glenn A N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions
EP2397125A1 (en) 2010-06-15 2011-12-21 Histocell, S.L. Antioxidant composition
US20120142550A1 (en) 2010-12-06 2012-06-07 Zehnder James L Vanin 1 as a Peripheral Blood Oxidative Stress Sensor
WO2013138744A1 (en) 2012-03-16 2013-09-19 M. Alphabet 1, Llc Compositions for the treatment of skin disorders
US20150148423A1 (en) * 2012-04-26 2015-05-28 Sentient Lifesciences, Inc. Use of n-acetylcysteine amide in the treatment of disease and injury
US20130303436A1 (en) 2012-12-06 2013-11-14 Stealth Peptides Internatioanl, Inc. Peptide therapeutics and methods for using same
US20150328337A1 (en) 2012-12-19 2015-11-19 The Johns Hopkins University Protection from oxidative damage by gene transfer by glutamate cysteine ligase and glutathione synthase
EP3122342B1 (en) 2014-03-28 2020-09-23 NaCuity Pharmaceuticals, Inc. Method for the preparation of n-acetyl cysteine amide
AU2015342831B2 (en) 2014-11-07 2019-09-12 Nacuity Pharmaceuticals, Inc. Treatment of retinitis pigmentosa with N-acetylcysteine amide
JP6849867B2 (ja) 2014-11-11 2021-03-31 ザ・ジョンズ・ホプキンス・ユニバーシティー 眼疾患を有する対象の治療に有用なバイオマーカー
AU2017235631B2 (en) 2016-03-17 2023-03-02 Thiogenesis Therapeutics, Inc. Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
CA3076392A1 (en) 2017-09-20 2019-03-28 Thiogenesis Therapeutics, Inc. Methods for the treatment of cysteamine sensitive disorders
AU2018338103B2 (en) 2017-09-20 2020-07-16 Nacuity Pharmaceuticals, Inc. Method for preparation of N-acetyl cysteine amide and derivatives thereof
WO2019060704A1 (en) 2017-09-22 2019-03-28 University Of Florida Research Foundation DEVICES AND METHODS FOR REDUCTION OF IN VIVO CYSTINE CRYSTALS
US20190135741A1 (en) 2017-11-09 2019-05-09 Nacuity Pharmaceuticals, Inc. Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress
GB2581656A (en) 2017-11-17 2020-08-26 Piraee Mahmood Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders
US20190151271A1 (en) 2017-11-21 2019-05-23 The Johns Hopkins University Compositions and methods for treatment of eye diseases
CN108618993B (zh) 2018-07-16 2021-07-27 广东格烯生物科技股份有限公司 一种美白组合物及其制备方法和应用
WO2020102810A1 (en) 2018-11-16 2020-05-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Thermoresponsive gel eye drop for ocular delivery of cysteamine
US12245998B2 (en) 2019-01-11 2025-03-11 Nacuity Pharmaceuticals, Inc. N-acetylcysteine amide (NACA) and (2R,2R′)-3,3′ disulfanediyl bis(2-acetamidopropanamide) (diNACA) for the prevention and treatment of radiation pneumonitis and treatment of pulmonary function in Cystic Fibrosis
KR102745520B1 (ko) 2019-01-11 2024-12-23 나쿠이티 파마슈티컬스, 인코포레이티드 방사선 피부염을 방지 및 치료하고 피부 라이트닝 또는 피부 화이트닝을 위한 n-아세틸시스테인 아미드(naca) 및 (2r,2r')-3,3'-디설판디일 비스(2-아세트아미도프로판아미드)(dinaca)
US11766413B2 (en) 2019-01-11 2023-09-26 Nacuity Pharmaceuticals, Inc. Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with n-acetylcysteine amide (NACA) or (2R,2R′)-3,3′-disulfanediyl BIS(2-acetamidopropanamide)(DiNACA)

Also Published As

Publication number Publication date
WO2016073931A1 (en) 2016-05-12
RU2711913C2 (ru) 2020-01-24
CA2967327A1 (en) 2016-05-12
EP3214934A4 (en) 2018-06-20
AU2019261762B2 (en) 2021-06-10
JP2025160381A (ja) 2025-10-22
AU2021225263B2 (en) 2023-11-02
CN107426997A (zh) 2017-12-01
US20180296503A1 (en) 2018-10-18
JP2021193119A (ja) 2021-12-23
HK1252822A1 (zh) 2019-06-06
AU2024200436A1 (en) 2024-02-08
RU2017119230A (ru) 2018-12-10
JP2017533969A (ja) 2017-11-16
BR112017009584A2 (pt) 2017-12-26
EP3214934A1 (en) 2017-09-13
US20170333375A1 (en) 2017-11-23
KR20220039853A (ko) 2022-03-29
AU2021225263A1 (en) 2021-09-30
AU2015342831A1 (en) 2017-05-25
US12472157B2 (en) 2025-11-18
JP2020023549A (ja) 2020-02-13
RU2017119230A3 (enExample) 2018-12-10
KR20170109527A (ko) 2017-09-29
EP4000612A1 (en) 2022-05-25
CA2967327C (en) 2020-04-28
AU2019261762A1 (en) 2019-11-28
WO2016073829A9 (en) 2016-06-23
AU2015342831B2 (en) 2019-09-12
JP2023145734A (ja) 2023-10-11
CN108498495A (zh) 2018-09-07
WO2016073829A2 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
AU2021225263B2 (en) Treatment of retinitis pigmentosa with n-acetylcysteine amide
US12458608B2 (en) N-Acetylcysteine Amide (NACA) and (2R,2R′)-3,3′ disulfanediyl BIS(2-acetamidopropanamide) (DINACA) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvement
US11766413B2 (en) Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with n-acetylcysteine amide (NACA) or (2R,2R′)-3,3′-disulfanediyl BIS(2-acetamidopropanamide)(DiNACA)
US20210228509A1 (en) Prodrug for the treatment of disease and injury of oxidative stress
US20230381120A1 (en) Treatment of Age-Related Macular Degeneration, Glaucoma, and Diabetic Retinopathy with N-Acetylcysteine Amide (NACA) or (2R,2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide)(DiNACA)

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E12 Pre-grant re-examination requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E12-REX-PX0901 (AS PROVIDED BY THE NATIONAL OFFICE)

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901